LAS VEGAS—Fibroblast growth factor 23 (FGF-23) is not significantly associated with dietary phosphorus or urinary phosphorus excretion, researchers reported at the National Kidney Foundation’s Spring Clinical Meetings.
Weekly (50,000 units) and monthly doses (50,000 units) of ergocalciferol treatment does not significantly impact markers of mineral metabolism (MM) in chronic hemodialysis (HD) patients, a study suggests.
New approach may ease problems with noncompliance, according to researchers.
Cinacalcet plus low-dose vitamin D for secondary hyperparathyroidism yielded encouraging results
Compared with incident hemodialysis (HD) patients, incident peritoneal dialysis (PD) patients, especially non-diabetics, show a robust and consistent survival advantage for up to five years.
Patients with renal disease who are well prepared to start dialysis are significantly more likely to survive their first year of treatment, according to a study presented at the National Kidney Foundation’s 2010 Spring Clinical Meetings.
Ferumoxytol, a novel IV iron replacement therapy for CKD patients with iron deficiency anemia, is well tolerated regardless of the number of injections or interval between injections.
Very high and very low parathyroid hormone (PTH) levels are associated with the highest mortality rates in hemodialysis (HD) patients.
Central venous catheters are the most prevalent access type in patients who initiated hemodialysis (HD) following a failed renal transplant.
Researchers who studied a group of non-dialysis CKD patients found that about one quarter of them suffered from iron deficiency anemia.
Please login or register first to view this content.
